NCT07162961View on ClinicalTrials.gov

Nintedanib for Improving Reproductive Outcomes in Adenomyosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Adenomyosis of Uterus
Interventions
DRUG

Nintedanib

Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.

DRUG

Progesterone

For control group

All Listed Sponsors
lead

Sun Yat-sen University

OTHER